Half-year report · Q2
4521.TEDINET S100UP1J
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 44
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥51.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥72.0bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥36.2bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥19.6bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥5.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥19.8bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥10.0bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥19.2bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥5.7bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥8.0bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥14.3bn | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥4.1bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥187.1bn | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥171.6bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥171.7bn | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥32.7bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥27.9bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥154.4bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥143.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥140.7bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥67.3bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥50.6bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥84.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥65.3bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥70.1bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥74.3bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥23.9bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥245m | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥2.4bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥5.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥1.1bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥2.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥5.7bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.8bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥377.23 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥212.67 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥108.18 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| Equity ratio | 82.5% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 83.8% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.0% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 18
| Segment | Item | Period | Value |
|---|---|---|---|
| jpcrp040300-q2r_E00935-000Medicinereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥50.1bn |
| jpcrp040300-q2r_E00935-000Medicinereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥50.1bn |
| jpcrp040300-q2r_E00935-000Medicinereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥18.9bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥676m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥51.4bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥51.4bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥19.6bn |
| jpcrp040300-q2r_E00935-000Medicinereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E00935-000Medicinereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥35.0bn |
| jpcrp040300-q2r_E00935-000Medicinereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥4.9bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥1.2bn |
| jpcrp040300-q2r_E00935-000Real Estatereportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥661m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥36.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥36.2bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥5.5bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 490
| Item | Context | Value | Unit |
|---|---|---|---|
| Net cash provided by used in financing activities | Prior1YTDDuration | -2813000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | -2839000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | － | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | － | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -4199000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | 18661000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 74260000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 65325000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 70060000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 83987000000 | JPY |
| Net sales of finished goods and merchandise | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 34192000000 | JPY |
| Net sales of finished goods and merchandise | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Net sales of finished goods and merchandise | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 34192000000 | JPY |
| Net sales of finished goods and merchandise | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales of finished goods and merchandise | Prior1YTDDuration | 34192000000 | JPY |
| Royalty | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 765000000 | JPY |
| Royalty | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Royalty | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 765000000 | JPY |
| Royalty | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Royalty | Prior1YTDDuration | 765000000 | JPY |
| Other income | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Other income | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | 1212000000 | JPY |
| Other income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 1212000000 | JPY |
| Other income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Other income | Prior1YTDDuration | 1212000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 34958000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | 1212000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 36171000000 | JPY |
| Revenues from external customers | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Revenues from external customers | Prior1YTDDuration | 36171000000 | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Transactions with other segments | Prior1YTDDuration | － | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 34958000000 | JPY |
| Net sales | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | 1212000000 | JPY |
| Net sales | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 36171000000 | JPY |
| Net sales | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales | Prior1YTDDuration | 36171000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 4851000000 | JPY |
| Operating income | Prior1YTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | 661000000 | JPY |
| Operating income | Prior1YTDDuration_TotalOfReportableSegmentsAndOthersMember | 5512000000 | JPY |
| Operating income | Prior1YTDDuration_ReconcilingItemsMember | － | JPY |
| Operating income | Prior1YTDDuration | 5512000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_jpcrp040300-q2r_E00935-000MedicineReportableSegmentsMember | 35363000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_jpcrp040300-q2r_E00935-000RealEstateReportableSegmentsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_TotalOfReportableSegmentsAndOthersMember | 35363000000 | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration_ReconcilingItemsMember | － | JPY |
| Net sales of finished goods and merchandise | CurrentYTDDuration | 35363000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |